Biomea Fusion reported a significantly narrower-than-expected net loss of $6.2 million for the third quarter of 2026, driven by an aggressive 41% year-over-year reduction in R&D expenses. The company reached a critical milestone by completing enrollment in its Phase II COVALENT-211 trial for lead candidate icovamenib, while signaling a pivot for its obesity program BMF-650 toward strategic partnerships.
Key Highlights
- Completed enrollment in the Phase II COVALENT-211 clinical trial for icovamenib in insulin-deficient type 2 diabetes, with topline data expected in the first quarter of 2027.
- Reported Phase I results for oral GLP-1 candidate BMF-650 showing 6.1% weight reduction in confined participants at Day 29, though management indicated further development will require a strategic partner.
- Reduced quarterly R&D spend to $8.5 million from $14.4 million YoY, primarily through headcount reductions and lower external consulting and manufacturing costs.
- Maintained a cash and equivalents balance of $26.8 million, which management projects is sufficient to fund operations into the second quarter of 2027.